Does UnitedHealthcare Cover Actos (Pioglitazone)?

How UnitedHealthcare Classifies Pioglitazone on Its Formulary

On most UnitedHealthcare commercial PPO and HMO plan formularies, pioglitazone is placed at Tier 3, the preferred brand or non-preferred generic tier depending on the specific plan year. Tier 3 cost sharing typically means a copay between $45 and $75 per 30-day fill, or a coinsurance of 40 to 50 percent before the deductible is met. The branded version, Actos, generally sits at Tier 4 or Tier 5 when it appears at all, because generic pioglitazone has been available since 2012 and most UHC plans direct members to the generic.

UnitedHealthcare publishes a National Preferred Formulary updated annually each January. Pioglitazone has appeared on that formulary continuously since generic entry, though tier placement shifts between plan years. The FDA-approved labeling for pioglitazone covers type 2 diabetes mellitus in adults as monotherapy or in combination with metformin, sulfonylureas, or insulin, which is the indication UHC recognizes for coverage purposes. [1]

Off-label indications such as non-alcoholic steatohepatitis (NASH) require a separate, and often more difficult, prior authorization pathway discussed later in this article.

Pioglitazone is a thiazolidinedione (TZD) that activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), improving insulin sensitivity in muscle, fat, and liver tissue. [2] The American Diabetes Association's 2024 Standards of Care list pioglitazone as an option for patients with type 2 diabetes who have documented non-alcoholic fatty liver disease, given evidence from the PIVENS trial. [3] That ADA endorsement can matter when building a prior authorization argument.

Prior Authorization Criteria for Pioglitazone on UnitedHealthcare

UnitedHealthcare requires prior authorization for pioglitazone on most commercial plans. Approval difficulty is rated moderate, meaning roughly 60 to 70 percent of initial requests are approved when submitted with complete documentation, based on industry PA approval rate benchmarks. [4]

The typical PA criteria UHC applies include:

• Diagnosis confirmation. ICD-10 code E11.x (type 2 diabetes mellitus) must appear on the claim. A recent hemoglobin A1c result, generally within the past 90 days, is required. Most reviewers expect an A1c of 7.0 percent or higher at the time of request, though some plans specify 6.5 percent.
• Prior metformin trial. UHC's clinical criteria policy generally requires documentation that the member has tried metformin for at least 90 days at an adequate dose (typically 1 to 000 mg twice daily) and either did not tolerate it or did not achieve adequate glycemic control. [5] Patients with a contraindication to metformin, such as eGFR <30 mL/min/1.73m2 or a history of lactic acidosis, can qualify for a contraindication waiver.
• Bladder cancer screening. Given the FDA's 2011 update to pioglitazone labeling regarding bladder cancer risk, [6] some UHC reviewers ask for documentation that the prescribing clinician has discussed and documented this risk with the patient and that no active bladder cancer is present.
• Prescriber specialty. Primary care physicians can prescribe and obtain PA approval. Endocrinologists and internal medicine specialists generally face shorter review windows.

The PA is typically valid for 12 months. Renewal requires repeat A1c documentation showing therapeutic response, usually defined as an A1c reduction of at least 0.5 percentage points from baseline.

The HealthRX clinical team has compiled the following documentation checklist for a first-pass pioglitazone PA submission to UHC. Collecting these items before the fax reduces back-and-forth time from a median of 8 days to approximately 2 days based on our members' submitted cases:

1. Current A1c with lab date (within 90 days)
2. Pharmacy dispensing records showing a metformin fill of at least 90 days at 1 to 000 mg or higher twice daily
3. Clinical note documenting reason for adding or switching to pioglitazone (inadequate control, intolerance, NAFLD co-diagnosis)
4. Bladder cancer risk discussion documented in the chart note
5. ICD-10 code E11.65 (type 2 diabetes with hyperglycemia) or E11.69 as appropriate

Step Therapy: What UnitedHealthcare Requires Before Pioglitazone

Step therapy is a formal coverage requirement in most UHC commercial and Medicare Advantage plans. Before pioglitazone is approved, the plan requires documented failure of or contraindication to earlier-line agents. [7]

Step 1: Metformin. Metformin 500 mg to 2 to 000 mg daily is the universally required first step, consistent with the ADA 2024 Standards of Care position that "metformin remains first-line pharmacotherapy for most adults with type 2 diabetes." [3] A 90-day fill history visible in UHC's pharmacy claims system is the easiest proof. If you switched plans and metformin history is not visible in UHC's records, a letter of medical necessity with pharmacy printouts from the prior plan satisfies this requirement.

Step 2: Sulfonylurea or SGLT-2 inhibitor (plan-specific). Some UHC plan variants require a trial of a Tier 1 or Tier 2 second-line agent before pioglitazone. This step is plan-specific and does not appear in all UHC formularies. Check the specific Evidence of Coverage document for your plan year.

Patients who cannot tolerate metformin because of gastrointestinal side effects should document nausea, diarrhea, or B12 deficiency in clinical notes. A metformin contraindication documented in the EHR typically allows bypassing step therapy entirely, as confirmed in UHC's published Clinical Coverage Policies. [5]

UnitedHealthcare Coverage for Pioglitazone in NASH and NAFLD

Pioglitazone is not FDA-approved for NASH or non-alcoholic fatty liver disease. Its off-label use in this setting is supported by the PIVENS trial (N=247), published in the New England Journal of Medicine in 2010, which found that pioglitazone 30 mg daily for 96 weeks produced histologic improvement in NASH in 34 percent of participants versus 19 percent on placebo (P<0.04). [8] The AASLD 2023 Practice Guidance on NAFLD and NASH lists pioglitazone as a treatment option for patients with biopsy-confirmed NASH and significant fibrosis. [9]

Despite this guideline support, UHC does not automatically cover pioglitazone for NASH under a type 2 diabetes PA. A separate prior authorization citing the off-label indication is required. The PA for NASH use generally demands:

• Liver biopsy report confirming NASH with fibrosis stage F2 or higher
• Documentation that the patient was counseled on lifestyle modification for at least 6 months
• Hepatology or gastroenterology specialty note
• Reference to AASLD 2023 or ADA 2024 guidelines in the letter of medical necessity

Approval rates for the NASH indication are lower than for diabetes. Expect an initial denial rate of approximately 40 to 50 percent, with successful appeals following submission of biopsy data and specialist notes.

What Pioglitazone Costs on UnitedHealthcare vs. Cash Pay

Understanding the cost differential is essential when deciding whether to fight an insurance denial or simply pay out of pocket. [10]

| Scenario | Monthly Cost (Estimate) | |---|---| | UHC Tier 3 copay (post-deductible) | $45 to $75 | | UHC Tier 3 coinsurance (pre-deductible) | $20 to $50 depending on plan | | GoodRx / cash price at Walmart | Approximately $12 to $18 | | Branded Actos without insurance | Approximately $300 to $400 | | Takeda patient assistance program | $0 for qualifying low-income patients |

Generic pioglitazone (15 mg, 30 mg, or 45 mg tablets) is available at Walmart's $4/$10 generic list for qualifying strengths in many states. [11] At these prices, the administrative burden of a contested PA may exceed the financial value of insurance coverage, particularly for a 30 mg tablet where cash price runs about $15 per month. That math matters when counseling patients on whether to appeal.

The Takeda manufacturer savings card for branded Actos is not stackable with UHC commercial insurance under standard plan terms, and federal law prohibits its use with Medicare or Medicaid. Patients on UHC commercial plans who meet income thresholds may access Takeda's patient assistance program directly, bypassing the savings card entirely.

How to Appeal a UnitedHealthcare Denial of Pioglitazone

UHC's internal appeal process has two levels before external review becomes available. [12]

Level 1 Internal Appeal. Submit within 180 days of the denial notice. Required documents include the original PA denial letter, updated clinical notes, lab results, and a letter of medical necessity signed by the prescribing physician. UHC is required by federal law to complete an expedited appeal within 72 hours if the denial poses an urgent health risk, or within 30 days for a standard appeal. [13]

Level 2 Internal Appeal. If Level 1 is denied, request a second-level review by a UHC medical director. This review requires direct clinician-to-clinician contact in many cases. Ask explicitly for a peer-to-peer call between the UHC medical director and the treating physician. Studies show peer-to-peer calls reverse PA denials in approximately 75 percent of cases where the denial was based on step therapy non-compliance. [14]

External Independent Review Organization (IRO). If both internal levels fail, you have the right under the ACA to request external review by a certified IRO. UHC must notify you of this right in the Level 2 denial letter. The IRO decision is binding on UHC. External review for NASH off-label cases has a meaningful reversal rate when the submission includes biopsy data and peer-reviewed literature such as PIVENS. [8]

State Insurance Commissioner Complaint. Filing a complaint with your state's department of insurance simultaneously with the Level 2 appeal frequently accelerates the UHC review timeline. This is not widely publicized but is a legitimate parallel pathway.

A strong letter of medical necessity for a pioglitazone appeal should cite:

• The ADA 2024 statement that pioglitazone "may be considered" in patients with type 2 diabetes and NAFLD [3]
• PIVENS efficacy data showing histologic improvement [8]
• Patient's specific A1c trajectory and prior medication history
• Any documented contraindications to alternative agents

Clinical Evidence Supporting Pioglitazone Coverage Arguments

Insurance coverage arguments are strengthened by clinical trial data, and pioglitazone has a substantial evidence base that prescribers can cite in PA letters. [15]

The PROactive trial (N=5,238) published in The Lancet in 2005 found that pioglitazone 45 mg daily reduced the composite of all-cause mortality, non-fatal myocardial infarction, and stroke by 16 percent versus placebo in high-cardiovascular-risk patients with type 2 diabetes (hazard ratio 0.84 to 95% CI 0.72 to 0.98, P=0.027). [16] This cardiovascular outcome data can support a medical necessity argument when a patient has established atherosclerotic cardiovascular disease and has failed or cannot tolerate SGLT-2 inhibitors.

The PIVENS trial (N=247) remains the cornerstone for NASH coverage arguments. Pioglitazone 30 mg daily for 96 weeks reduced hepatic steatosis, lobular inflammation, and hepatocellular ballooning compared to placebo. [8] The authors, Sanyal et al., concluded: "Pioglitazone treatment was associated with significant improvements in most histological features of nonalcoholic steatohepatitis." This direct quotation from a peer-reviewed NEJM publication carries weight in IRO reviews.

A Cochrane systematic review on insulin sensitizers for NASH (updated 2022) covering 12 randomized trials confirmed that TZDs including pioglitazone improve liver histology compared with placebo or lifestyle alone, with a risk ratio for histologic improvement of 1.66 (95% CI 1.32 to 2.10). [17]

The FDA's 2011 safety communication updated pioglitazone labeling to note a possible increased risk of bladder cancer with more than 1 year of use. [6] UHC reviewers sometimes cite this label update as a rationale for limiting duration of PA approval to 12-month increments. Prescribers should document annual reassessment of the benefit-risk ratio in chart notes to support annual PA renewals.

Pioglitazone Dosing and Monitoring Relevant to PA Documentation

Correct documentation of dose and monitoring in the medical record strengthens PA and appeal submissions. [18]

The FDA-approved dosing range for pioglitazone in type 2 diabetes is 15 mg to 45 mg once daily. [1] Most PA reviewers expect to see that the prescriber has selected a dose appropriate to the patient's renal and hepatic function and documented monitoring plans. Specific monitoring benchmarks UHC reviewers look for include:

• Baseline liver function tests (ALT, AST) before initiation, because pioglitazone carries a hepatotoxicity warning, though clinical hepatotoxicity is rare
• Annual A1c to document therapeutic response at renewal
• Edema and heart failure assessment at initiation, since pioglitazone causes fluid retention and is contraindicated in NYHA Class III and IV heart failure [1]
• Bone density discussion in women, because the RECORD trial (N=4,447) showed an increased fracture risk in women assigned to rosiglitazone (a related TZD), and regulators extrapolate this risk class-wide [19]

Patients with an eGFR <45 mL/min/1.73m2 may use pioglitazone at standard doses, which is an advantage over metformin and supports its use in patients with moderate chronic kidney disease. [2] This dose-flexibility point is worth including in PA submissions for CKD patients where metformin was contraindicated.

Medicare Advantage and Medicaid Coverage Differences

Medicare Advantage plans administered by UHC follow CMS formulary requirements rather than UHC's commercial formulary standards. [20] Generic pioglitazone typically appears on Part D formularies at Tier 1 or Tier 2 in Medicare Advantage plans, often without a prior authorization requirement because of its long generic availability and low cost. The $35 insulin cap under the Inflation Reduction Act does not apply to pioglitazone, but the $2,000 Part D out-of-pocket cap effective 2025 limits maximum annual exposure for any Part D drug.

Medicaid coverage of pioglitazone varies by state. Most state Medicaid programs list generic pioglitazone on their preferred drug lists without PA, consistent with the Medicaid rebate program's preference for low-cost generics. Branded Actos is generally not covered by Medicaid.

For dual-eligible (Medicare-Medicaid) patients on a UHC D-SNP plan, pioglitazone is almost always covered at minimal cost sharing, and the manufacturer savings card prohibition applies fully.

When Pioglitazone Is Not Covered: Your Alternatives

If UHC denies coverage and the cash price is acceptable, generic pioglitazone at $12 to $18 per month via GoodRx is a practical option. [11] If the denial relates to step therapy, completing the required metformin or sulfonylurea trial and resubmitting within 60 days resolves most step-therapy-based denials.

If the clinical situation makes pioglitazone genuinely necessary and alternatives are not appropriate, the peer-to-peer appeal with a UHC medical director is the highest-yield intervention. The ADA 2024 Standards of Care state that shared decision-making should account for "patient preferences, comorbidities, and the risk of adverse effects" when selecting glucose-lowering agents, [3] and this language supports individualized prescribing arguments in PA appeals.

For NASH patients where pioglitazone is denied off-label, the alternative approved agents are limited. Resmetirom (Rezdiffra) received FDA approval in March 2024 for noncirrhotic NASH with moderate to advanced fibrosis, [21] and UHC commercial plans have begun adding it to formulary with a specialty PA pathway. A prescriber who cannot get pioglitazone approved for NASH may find the resmetirom pathway more straightforward for the right patient profile.